Related content

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

By Wu Jie   Zhu Yiqing   Jiang Yunfei   Cao Yaoping  

Gynecological Endocrinology, Vol. 24, Iss. 7, 2008-01 ,pp. : 392-398

Informa Healthcare

Access to resources Recommend Favorite

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial

By Fux Otta CarolinaFux   Wior Myriam   Iraci Gabriel S.   Kaplan Raquel   Torres Diana   Gaido María Isabel   Wyse Eduardo P.  

Gynecological Endocrinology, Vol. 26, Iss. 3, 2010-03 ,pp. : 173-178

Informa Healthcare

Access to resources Recommend Favorite

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

By Sahin I   Serter R   Karakurt F   Demirbas B   Culha C   Taskapan C   Kosar F   Aral Y  

Gynecological Endocrinology, Vol. 19, Iss. 3, 2004-09 ,pp. : 115-124

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

By Glueck Charles J.   Moreira Andrew   Goldenberg Naila   Sieve Luann   Wang Ping  

Human Reproduction, Vol. 18, Iss. 8, 2003-08 ,pp. : 1618-1625

Oxford University Press

Access to resources Recommend Favorite

Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects

By Nardo L. G.   Rai R.  

Gynecological Endocrinology, Vol. 15, Iss. 5, 2001-10 ,pp. : 373-380

Informa Healthcare

Access to resources Recommend Favorite